Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells

Tang, Zhao; Du, Wenjing; Xu, Fei; Sun, Xianjun; Chen, Wenjing; Cui, Jie; Tang, Weifeng; Yang, Fangyong; Teng, Fangzhou; Lin, Jinpei; Liu, Baojun; Dong, Jingcheng

doi:10.7150/ijbs.66630



Theranostics

International Journal of Medical Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Biol Sci 2022; 18(5):2060-2074. doi:10.7150/ijbs.66630 This issue Cite

Research Paper

Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells

Zhao Tang^1,2#, Wenjing Du^1,2#, Fei Xu^1,2, Xianjun Sun^1,2, Wenjing Chen^1,2, Jie Cui^1,2, Weifeng Tang^1,2, Fangyong Yang^1,2, Fangzhou Teng^1,2, Jinpei Lin³, Baojun Liu^1,2✉, Jingcheng Dong^1,2✉

1. Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
2. Institutes of Integrative Medicine, Fudan University, Shanghai, China.
3. Department of Integrated TCM & Western Medicine Department, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China.
#These authors contributed equally to this work.

Citation:

Tang Z, Du W, Xu F, Sun X, Chen W, Cui J, Tang W, Yang F, Teng F, Lin J, Liu B, Dong J. Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells. Int J Biol Sci 2022; 18(5):2060-2074. doi:10.7150/ijbs.66630. https://www.ijbs.com/v18p2060.htm

Other styles

Abstract

Although cisplatin is the most effective first-line drug in the management of advanced non-small cell lung cancer (NSCLC), drug resistance remains a major clinical challenge. There is increasing evidence that icariside II (IS) exhibits antitumour activity in a variety of cancers. In the current study, we investigated the anticancer effects of icariside II combined with cisplatin and elucidated the underlying mechanism in NSCLC. Here, we showed that cotreatment with IS and cisplatin inhibited cell proliferation and induced cellular apoptosis. Using mRNA sequencing (mRNA-seq), we identified differentially expressed genes (DEGs) in which there was an enrichment in PERK-mediated unfolded protein response (UPR) signalling. The western blot results revealed that IS activated endoplasmic reticulum (ER) stress, including three branches of UPR signalling, PERK, IRE1 and ATF6, and the downstream PERK-eIF2α-ATF4-CHOP pathway, thus potentiating the apoptosis induced by cisplatin. In addition, the combination of IS with cisplatin significantly reduced xenograft tumour growth in C57BL/6 and BALB/c nude mice in vivo. Notably, the combination therapy displayed no evident toxicity. Taken together, IS enhances cisplatin-induced apoptosis partially by promoting ER stress signalling in NSCLC, suggesting that combination treatment with IS and cisplatin is a novel potential therapeutic strategy for NSCLC.

Keywords: icariside II, lung cancer, cisplatin, apoptosis, endoplasmic reticulum stress, unfolded protein response

Citation styles

APA

Tang, Z., Du, W., Xu, F., Sun, X., Chen, W., Cui, J., Tang, W., Yang, F., Teng, F., Lin, J., Liu, B., Dong, J. (2022). Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells. International Journal of Biological Sciences, 18(5), 2060-2074. https://doi.org/10.7150/ijbs.66630.

ACS

Tang, Z.; Du, W.; Xu, F.; Sun, X.; Chen, W.; Cui, J.; Tang, W.; Yang, F.; Teng, F.; Lin, J.; Liu, B.; Dong, J. Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells. Int. J. Biol. Sci. 2022, 18 (5), 2060-2074. DOI: 10.7150/ijbs.66630.

NLM

CSE

Tang Z, Du W, Xu F, Sun X, Chen W, Cui J, Tang W, Yang F, Teng F, Lin J, Liu B, Dong J. 2022. Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells. Int J Biol Sci. 18(5):2060-2074.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.